Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A nant (new approaches to neuroblastoma therapy) trial

Journal of Clinical Oncology

Volumn 34, Issue 12, 2016, Pages 1368-1375

  DuBois, Steven G ^a   Marachelian, Araz ^b   Fox, Elizabeth ^d   Kudgus, Rachel A ^e   Reid, Joel M ^e   Groshen, Susan ^b   Malvar, Jemily ^b   Bagatell, Rochelle ^d   Wagner, Lars ^f   Maris, John M ^d   Hawkins, Randall ^c   Courtier, Jesse ^c   Lai, Hollie ^b   Goodarzian, Fariba ^b   Shimada, Hiroyuki ^b   Czarnecki, Scarlett ^b   Tsao Wei, Denice ^b   Matthay, Katherine K ^c   Mosse, Yael P ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; ALANINE AMINOTRANSFERASE; ALISERTIB; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CEFIXIME; CEFPODOXIME; CREATINE; DRUG METABOLITE; FIRTECAN; FIRTECAN GLUCURONIDE; GAMMA GLUTAMYLTRANSFERASE; GROWTH FACTOR; IRINOTECAN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AURORA A KINASE; AZEPINE DERIVATIVE; CAMPTOTHECIN; DACARBAZINE; GLUCURONOSYLTRANSFERASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TABLET; UGT1A1 ENZYME;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; COUGHING; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; LEG PAIN; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; GENOTYPE; INFANT; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHENOTYPE; PRESCHOOL CHILD; TABLET; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AURORA KINASE A; AZEPINES; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PHENOTYPE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TABLETS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84963799476     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.4889     Document Type: Article

References (32)

1. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007
2. Bagatell R, London WB, Wagner LM, et al: Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 29:208-213, 2011
3. Wagner LM, Villablanca JG, Stewart CF, et al: Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approach to neuroblastoma therapy consortium study. J Clin Oncol 27:1290-1296, 2009
4. Friedberg JW, Mahadevan D, Cebula E, et al: Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressiveB- and T-cell non-Hodgkin lymphomas. J Clin Oncol 32:44-50, 2014
5. Matulonis UA, Sharma S, Ghamande S, et al: Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127:63-69, 2012
6. Cervantes A, Elez E, Roda D, et al: Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18:4764-4774, 2012
7. Dees EC, Cohen RB, Von Mehren M, et al: Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18:4775-4784, 2012
8. Sarantopoulos J, Hahn NM, Higano CS, et al: Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel in patients with advanced solid tumors, including castrationresistant prostate cancer. Presented at Am Soc Clin Oncol Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014
9. Kim EJ, Semrad TJ, Gandara DR, et al: Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors. J Clin Oncol 33, 2015 (abstr 2526)
10. Falchook G, Goff BA, Kurzrock R, et al: Oral MLN8237 with weekly paclitaxel in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer, or breast cancer: Preliminary phase 1 results. Presented at European Soc Gynaecol Oncol, Liverpool, United Kingdom, October 19-22, 2013
11. Mossé YP, Lipsitz E, Fox E, et al: Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: A Children's Oncology Group Phase I Consortium study. Clin Cancer Res 18:6058-6064, 2012
12. Brockmann M, Poon E, Berry T, et al: Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24:75-89, 2013
13. Gustafson WC, Meyerowitz JG, Nekritz EA, et al: Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26:414-427, 2014
14. Otto T, Horn S, Brockmann M, et al: Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15:67-78, 2009
15. Ramani P, Nash R, Rogers CA: Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma. Histopathology 66:370-379, 2014
16. Shang X, Burlingame SM, Okcu MF, et al: Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 8:2461-2469, 2009
17. Maris JM, Morton CL, Gorlick R, et al: Initial testing of the Aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55:26-34, 2010
18. Lipsitz E, Nguyen V, Zhao H, et al: Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan and temozolomide in neuroblastoma. Presented at Am Soc Clin Oncol, Chicago, IL, June 4-8, 2010
19. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
20. Wagner LM, Crews KR, Stewart CF, et al: Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 50:201-207, 2008
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Ady N, Zucker JM, Asselain B, et al: A new 123I-MIBG whole body scan scoring method: Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 31 A: 256-261, 1995
23. Lipsitz E, Moorthy G, Mosse Y, et al: A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 878:2369-2373, 2010
24. Santisteban M, Buckner JC, Reid JM, et al; North Central Cancer Treatment Group: Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 92:165-175, 2009
25. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). Series on Drugs and the Pharmaceutical Sciences, Marcel Dekker Inc, NY, 1982
26. Goetz MP, McKean HA, Reid JM, et al: UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs 31:1559-1567, 2013
27. Akaba K, Kimura T, Sasaki A, et al: Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: A common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 46:21-26, 1998
28. Skolnik JM, Barrett JS, Jayaraman B, et al: Shortening the timeline of pediatric phase I trials: The rolling six design. J Clin Oncol 26:190-195, 2008
29. Mascarenhas L, Lyden ER, Breitfeld PP, et al: Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 28:4658-4663, 2010
30. O'Leary J, Muggia FM: Camptothecins: A review of their development and schedules of administration. Eur J Cancer 34:1500-1508, 1998
31. Bomgaars LR, Bernstein M, Krailo M, et al: Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 25:4622-4627, 2007
32. Yang JJ, Li Y, Chakravarty A, et al: Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237). Drug Metab Lett 7:96-104, 2014